| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL17A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL17A抗体的3-4篇参考文献及其摘要内容：
---
1. **文献名称**：*Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials*
**作者**：Langley RG, et al.
**摘要**：两项III期临床试验评估了IL-17A单抗Secukinumab治疗中重度斑块状银屑病的疗效和安全性。结果显示，与安慰剂和依那西普(TNF抑制剂)相比，Secukinumab显著改善皮损清除率(PASI 90应答率)，且耐受性良好。
2. **文献名称**：*Ixekizumab for the Treatment of Psoriasis: 60-Week Results from Two Phase III Trials*
**作者**：Leonardi C, et al.
**摘要**：III期临床试验证实，IL-17A抗体Ixekizumab在治疗中重度银屑病患者中，第12周时达到PASI 75/90的患者比例显著高于安慰剂和依那西普，长期使用(60周)维持疗效且未增加严重不良反应风险。
3. **文献名称**：*Secukinumab in Ankylosing Spondylitis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial*
**作者**：Baeten D, et al.
**摘要**：该研究首次证明IL-17A抑制剂Secukinumab对活动性强直性脊柱炎患者有效。治疗组在16周时达到ASAS20缓解标准的比例显著高于安慰剂组，且安全性可控，支持IL-17A通路在该疾病中的治疗价值。
4. **文献名称**：*Efficacy and Safety of Secukinumab in Patients with Psoriatic Arthritis: A Meta-Analysis of Randomized Controlled Trials*
**作者**：McInnes IB, et al.
**摘要**：通过分析多项随机对照试验，发现Secukinumab可显著改善银屑病关节炎患者的关节症状和皮肤表现，ACR20应答率优于安慰剂，且长期治疗中感染等不良事件发生率与对照组无显著差异。
---
以上文献均聚焦于IL-17A抗体在自身免疫性疾病中的临床应用，涵盖银屑病、银屑病关节炎及强直性脊柱炎，提供关键疗效与安全性数据。
Interleukin-17A (IL-17A), a pro-inflammatory cytokine primarily secreted by Th17 cells, plays a pivotal role in host defense and inflammatory pathologies. As a member of the IL-17 family, it binds to the IL-17 receptor complex (IL-17RA/RC), triggering signaling cascades that induce antimicrobial peptides, chemokines, and inflammatory mediators. Dysregulated IL-17A production is strongly linked to autoimmune and chronic inflammatory diseases, including psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.
The development of IL-17A-targeting monoclonal antibodies (mAbs) emerged as a breakthrough in modulating these conditions. Drugs like secukinumab and ixekizumab, approved since the 2010s, bind directly to IL-17A, neutralizing its interaction with receptors and suppressing downstream inflammation. Clinical trials demonstrated significant efficacy in reducing disease activity and improving patient outcomes, particularly in plaque psoriasis where IL-17A drives keratinocyte hyperproliferation. However, safety considerations include increased susceptibility to infections, reflecting IL-17A's role in mucosal immunity.
Ongoing research explores broader applications, combination therapies, and biomarkers for treatment response. These antibodies exemplify the shift toward precision immunology, targeting specific cytokine pathways while highlighting the complexity of balancing therapeutic benefits with immune homeostasis.
×
